Initial Stage of Cutaneous Primary Melanoma Plays a Key Role in the Pattern and Timing of Disease Recurrence
DOI:
https://doi.org/10.2340/00015555-3832Keywords:
melanoma, follow-up studies, cutaneous malignant, disease progression, recurrence, metastasis, survivalAbstract
Given recent developments in the treatment of metastatic melanoma, early detection of disease recurrence is crucial. The aim of this single-centre retrospective cohort study was to investigate the impact of the initial stage of primary melanoma on the pattern and timing of disease recurrence and post-recurrence survival. Patients diagnosed with cutaneous melanoma with initial stage IA–IIID, between January 1996 and December 2018 and who developed disease recurrence until May 2019 were included (n = 784). Earlier stage at diagnosis was associated with a higher proportion of locoregional and a lower proportion of distant metastasis (p = 0.01). The median time to first metastasis decreased with the more advanced stages at initial diagnosis: 3.32 years (interquartile range (IQR) 1.72–6.14 years) for stage I, 1.85 years (IQR 0.99–3.78 years) for stage II and 1.19 years (IQR 0.70–2.42 years) for stage III disease (p < 0.001). These findings add evidence that American Joint Committee on Cancer stages at initial diagnosis of melanoma play a key role in the pattern and timing of disease recurrence and may be helpful to improve surveillance strategies in the follow-up of patients with melanoma.
Downloads
References
Miller AJ, Mihm MC, Jr. Melanoma. N Engl J Med 2006; 355: 51–65.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69: 7–34.
Karimkhani C, Green AC, Nijsten T, Weinstock MA, Dellavalle RP, Naghavi M, et al. The global burden of melanoma: results from the Global Burden of Disease Study 2015. Br J Dermatol 2017; 177: 134–140.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7–30.
Leiter U, Meier F, Schittek B, Garbe C. The natural course of cutaneous melanoma. J Surg Oncol 2004; 86: 172–178.
Meier F, Will S, Ellwanger U, Schlagenhauff B, Schittek B, Rassner G, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002; 147: 62–70.
Mervic L. Time course and pattern of metastasis of cutaneous melanoma differ between men and women. PLoS One 2012; 7: e32955.
Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67: 472–492.
Ribero S, Podlipnik S, Osella-Abate S, Sportoletti-Baduel E, Manubens E, Barreiro A, et al. Ultrasound-based follow-up does not increase survival in early-stage melanoma patients: a comparative cohort study. Eur J Cancer 2017; 85: 59–66.
Podlipnik S, Carrera C, Sánchez M, Arguis P, Olondo ML, Vilana R, et al. Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: a prospective cohort study. J Am Acad Dermatol 2016; 75: 516–524.
Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007; 4: e297.
RStudio: Integrated Development Environment for R. RStudio, PBC, Boston, MA, USA. 2018. Avaialble from https://support.rstudio.com/hc/en-us/articles/206212048-Citing-RStudio.
Team RC. R: A Language and environment for statistical computing. Vienna, 2019. Avaialble from https://www.r-project.org/.
Tas F, Erturk K. Relapse patterns in patients with local and regional cutaneous melanoma. Clin Transl Oncol 2019; 21: 412–419.
Lee AY, Droppelmann N, Panageas KS, Zhou Q, Ariyan CE, Brady MS, et al. Patterns and timing of initial relapse in pathologic stage II melanoma patients. Ann Surg Oncol 2017; 24: 939–946.
Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol 2010; 28: 3042–3047.
Skobe M, Detmar M. Structure, function, and molecular control of the skin lymphatic system. J Investig Dermatol Symp Proc 2000; 5: 14–19.
Braverman IM, Keh-Yen A. Ultrastructure of the human dermal microcirculation. III. The vessels in the mid- and lower dermis and subcutaneous fat. J Invest Dermatol 1981; 77: 297–304.
Baade PD, Whiteman DC, Janda M, Cust AE, Neale RE, Smithers BM, et al. Long-term deaths from melanoma according to tumor thickness at diagnosis. Int J Cancer 2020; 147: 1391–1396.
Faries MB, Steen S, Ye X, Sim M, Morton DL. Late recurrence in melanoma: clinical implications of lost dormancy. J Am Coll Surg 2013; 217: 27–34; discussion 34–26.
Ossowski L, Aguirre-Ghiso JA. Dormancy of metastatic melanoma. Pigment Cell Melanoma Res 2010; 23: 41–56.
Senft D, Ronai ZA. Immunogenic, cellular, and angiogenic drivers of tumor dormancy – a melanoma view. Pigment Cell Melanoma Res 2016; 29: 27–42.
Hohnheiser AM, Gefeller O, Gohl J, Schuler G, Hohenberger W, Merkel S. Malignant melanoma of the skin: long-term follow-up and time to first recurrence. World J Surg 2011; 35: 580–589.
Tas F, Erturk K. Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors. Melanoma Res 2017; 27: 134–139.
Leeneman B, Franken MG, Coupe VMH, Hendriks MP, Kruit W, Plaisier PW, et al. Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma. Eur J Surg Oncol 2019; 45: 825–831.
Wilson MA, Zhong J, Rosenbaum BE, Utter K, Moran U, Darvishian F, et al. Impact of initial stage on metastatic melanoma survival. Melanoma Res 2019; 29: 281–288.
Coit DG, Thompson JA, Albertini MR, Barker C, Carson WE, Contreras C, et al. Cutaneous melanoma, Version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2019; 17: 367–402.
Dummer R, Hauschild A, Guggenheim M, Keilholz U, Pentheroudakis G. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 Suppl 7: vii86–91.
Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, et al. Malignant melanoma S3-guideline “diagnosis, therapy and follow-up of melanoma”. J Dtsch Dermatol Ges 2013; 11: 1–116, 111–126.
Whiteman DC, Baade PD, Olsen CM. More people die from thin melanomas (1 mm) than from thick melanomas (>4 mm) in Queensland, Australia. J Invest Dermatol 2015; 135: 1190–1193.
Landow SM, Gjelsvik A, Weinstock MA. Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992–2013. J Am Acad Dermatol 2017; 76: 258–263.
Gastman BR, Gerami P, Kurley SJ, Cook RW, Leachman S, Vetto JT. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. J Am Acad Dermatol 2019; 80: 149–157.e144.
Podlipnik S, Carrera C, Boada A, Richarz NA, Lopez-Estebaranz JL, Pinedo-Moraleda F, et al. Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients. A prospective multicentre cohort study. J Eur Acad Dermatol Venereol 2019; 33: 857–862.
Zager JS, Gastman BR, Leachman S, Gonzalez RC, Fleming MD, Ferris LK, et al. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer 2018; 18: 130.
Gerami P, Cook RW, Wilkinson J, Russell MC, Dhillon N, Amaria RN, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res 2015; 21: 175–183.
McEvoy AC, Pereira MR, Reid A, Pearce R, Cowell L, Al-Ogaili Z, et al. Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies. Oncotarget 2019; 10: 113–122.
Calbet-Llopart N, Potrony M, Tell-Martí G, Carrera C, Barreiro A, Aguilera P, et al. Detection of cell-free circulating BRAF(V) (600E) by droplet digital polymerase chain reaction in patients with and without melanoma under dermatological surveillance. Br J Dermatol 2020; 182: 382–389.
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
